Sun Min Lim1,2, Hyunki Kim3, Beodeul Kang4, Hyo Song Kim1, Sun Young Rha1, Sung Hoon Noh5, Woo Jin Hyung5, Jae-Ho Cheong5, Hyoung-Il Kim5, Hyun Cheol Chung1, Mijin Yun6, Arthur Cho7, Minkyu Jung8. 1. Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. 2. Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Seongnam, Gyeonggido, 13496, Republic of Korea. 3. Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. 4. Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 5. Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea. 6. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. 7. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. artycho@yuhs.ac. 8. Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. minkjung@yuhs.ac.
Abstract
OBJECTIVE: Gastric neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are very rare, aggressive tumors of the stomach. We aimed to examine predictive role of pretreatment (18)F-FDG PET/CT-assessed metabolic parameter of primary tumors and metastases in patients with gastric NEC and MANEC. METHODS: We conducted a review of the 27 patients with histopathologically confirmed NECs (n = 10) and MANEC (n = 17) of the stomach at our institution between January 2005 and December 2012. All patients underwent (18)F-FDG-PET examination at diagnosis. Metabolic parameters [SUVmax, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] of the primary tumor and metastases on baseline PET/CT were analyzed. RESULTS: The median follow-up duration was 39.4 months (95 % CI 20.0-58.1 months) and the median overall survival (OS) was 25.7 months (95 % CI 14.1-37.2 months). All gastric lesions were well visualized (average SUVmax = 12.0, range 3.0-41.8). When subjects were divided into two groups by ROC cut-off value of 210.9 and 612, patients with high TLG in primary lesion and metastases showed poorer prognosis compared to low TLG patients (P = 0.09, P = 0.002, respectively). In the sub-analysis of patients with metastasis (n = 12), patients with high TLG in whole body tumor showed significantly shorter OS compared to those with low TLG (31.7 ± 11.4 vs. 7.2 ± 2.1 months, P = 0.006). CONCLUSION: (18)F-FDG PET/CT is useful in evaluating prognosis of advanced gastric cancer with neuroendocrine carcinoma components. Baseline MTV of primary gastric cancer with metastatic disease, and MTV, TLG of metastases may be prognostic markers in patients with gastric NEC and MANEC.
OBJECTIVE: Gastric neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are very rare, aggressive tumors of the stomach. We aimed to examine predictive role of pretreatment (18)F-FDG PET/CT-assessed metabolic parameter of primary tumors and metastases in patients with gastric NEC and MANEC. METHODS: We conducted a review of the 27 patients with histopathologically confirmed NECs (n = 10) and MANEC (n = 17) of the stomach at our institution between January 2005 and December 2012. All patients underwent (18)F-FDG-PET examination at diagnosis. Metabolic parameters [SUVmax, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] of the primary tumor and metastases on baseline PET/CT were analyzed. RESULTS: The median follow-up duration was 39.4 months (95 % CI 20.0-58.1 months) and the median overall survival (OS) was 25.7 months (95 % CI 14.1-37.2 months). All gastric lesions were well visualized (average SUVmax = 12.0, range 3.0-41.8). When subjects were divided into two groups by ROC cut-off value of 210.9 and 612, patients with high TLG in primary lesion and metastases showed poorer prognosis compared to low TLGpatients (P = 0.09, P = 0.002, respectively). In the sub-analysis of patients with metastasis (n = 12), patients with high TLG in whole body tumor showed significantly shorter OS compared to those with low TLG (31.7 ± 11.4 vs. 7.2 ± 2.1 months, P = 0.006). CONCLUSION: (18)F-FDG PET/CT is useful in evaluating prognosis of advanced gastric cancer with neuroendocrine carcinoma components. Baseline MTV of primary gastric cancer with metastatic disease, and MTV, TLG of metastases may be prognostic markers in patients with gastric NEC and MANEC.
Authors: Esben Andreas Carlsen; Camilla Bardram Johnbeck; Mathias Loft; Andreas Pfeifer; Peter Oturai; Seppo W Langer; Ulrich Knigge; Claes Nøhr Ladefoged; Andreas Kjaer Journal: J Nucl Med Date: 2021-02-26 Impact factor: 11.082
Authors: Melissa Frizziero; Bipasha Chakrabarty; Bence Nagy; Angela Lamarca; Richard A Hubner; Juan W Valle; Mairéad G McNamara Journal: J Clin Med Date: 2020-01-19 Impact factor: 4.241
Authors: Melissa Frizziero; Xin Wang; Bipasha Chakrabarty; Alexa Childs; Tu V Luong; Thomas Walter; Mohid S Khan; Meleri Morgan; Adam Christian; Mona Elshafie; Tahir Shah; Annamaria Minicozzi; Wasat Mansoor; Tim Meyer; Angela Lamarca; Richard A Hubner; Juan W Valle; Mairéad G McNamara Journal: World J Gastroenterol Date: 2019-10-21 Impact factor: 5.742